JP2008528033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528033A5 JP2008528033A5 JP2007553266A JP2007553266A JP2008528033A5 JP 2008528033 A5 JP2008528033 A5 JP 2008528033A5 JP 2007553266 A JP2007553266 A JP 2007553266A JP 2007553266 A JP2007553266 A JP 2007553266A JP 2008528033 A5 JP2008528033 A5 JP 2008528033A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- nucleic acid
- polypeptide
- acid molecule
- heterologous polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 102000040430 polynucleotide Human genes 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 17
- 239000002157 polynucleotide Substances 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 14
- 238000000034 method Methods 0.000 claims 6
- 230000028327 secretion Effects 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000003248 secreting effect Effects 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108010042106 Collagen Type IX Proteins 0.000 claims 2
- 102000004427 Collagen Type IX Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 108091005703 transmembrane proteins Proteins 0.000 claims 2
- 102000035160 transmembrane proteins Human genes 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 102100040512 Collagen alpha-1(IX) chain Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000007437 Fetuin-B Human genes 0.000 claims 1
- 108010086121 Fetuin-B Proteins 0.000 claims 1
- 101000749901 Homo sapiens Collagen alpha-1(IX) chain Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000008072 Lymphokines Human genes 0.000 claims 1
- 108010074338 Lymphokines Proteins 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 claims 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229950010131 puromycin Drugs 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64701305P | 2005-01-27 | 2005-01-27 | |
| PCT/US2006/002951 WO2006081430A2 (en) | 2005-01-27 | 2006-01-27 | Leader sequences for directing secretion of polypeptides and methods for production thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009009381A Division JP2009131268A (ja) | 2005-01-27 | 2009-01-19 | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528033A JP2008528033A (ja) | 2008-07-31 |
| JP2008528033A5 true JP2008528033A5 (enExample) | 2009-03-05 |
Family
ID=36741080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553266A Pending JP2008528033A (ja) | 2005-01-27 | 2006-01-27 | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
| JP2009009381A Pending JP2009131268A (ja) | 2005-01-27 | 2009-01-19 | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009009381A Pending JP2009131268A (ja) | 2005-01-27 | 2009-01-19 | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080286834A1 (enExample) |
| EP (1) | EP1841874B1 (enExample) |
| JP (2) | JP2008528033A (enExample) |
| AT (1) | ATE454455T1 (enExample) |
| AU (1) | AU2006207999A1 (enExample) |
| CA (1) | CA2589895A1 (enExample) |
| DE (1) | DE602006011574D1 (enExample) |
| DK (1) | DK1841874T3 (enExample) |
| WO (1) | WO2006081430A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| JP5376948B2 (ja) | 2005-09-13 | 2013-12-25 | ナショナル リサーチ カウンシル オブ カナダ | 腫瘍細胞活性を調節する方法及び組成物 |
| US9060961B2 (en) * | 2006-11-09 | 2015-06-23 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| WO2009056330A1 (en) * | 2007-10-31 | 2009-05-07 | Eth Zurich | Soluble truncated apom proteins and medical uses thereof |
| EP2271358B1 (en) * | 2008-03-25 | 2018-11-21 | Amarantus Therapeutics, Inc. | use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease |
| FR2933773B1 (fr) * | 2008-07-10 | 2013-02-15 | Biomerieux Sa | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal |
| RU2509774C2 (ru) | 2008-08-04 | 2014-03-20 | Файв Прайм Терапьютикс, Инк. | Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов |
| US8470554B2 (en) * | 2008-12-22 | 2013-06-25 | St. Jude Children's Research Hospital | Prokaryotic expression of soluble, active Dkk |
| JP2010183885A (ja) * | 2009-02-13 | 2010-08-26 | Kobe Univ | タンパク質の製造方法およびそれに用いる発現ベクター |
| EP2478003A4 (en) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4 |
| US8614183B2 (en) | 2009-11-13 | 2013-12-24 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| WO2011063523A1 (en) | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| EP2512501A4 (en) | 2009-12-17 | 2014-01-01 | Five Prime Therapeutics Inc | METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS |
| AU2011248083B2 (en) | 2010-05-04 | 2015-09-10 | Five Prime Therapeutics, Inc. | Antibodies that bind CSF1R |
| US8431532B2 (en) | 2010-06-28 | 2013-04-30 | Five Prime Therepeutics, Inc. | FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same |
| EP2444495A1 (en) * | 2010-10-20 | 2012-04-25 | Algenics | Secretion of recombinant polypeptides in the extracellular medium of diatoms |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| NZ703786A (en) | 2010-11-15 | 2016-08-26 | Five Prime Therapeutics Inc | Fgfr1 extracellular domain combination therapies |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| WO2012097238A2 (en) | 2011-01-14 | 2012-07-19 | Five Prime Therapeutics, Inc. | Il-27 antagonists for treating inflammatory diseases |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| CA2862739A1 (en) | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| MX2014015041A (es) | 2012-06-08 | 2015-06-17 | Shire Human Genetic Therapies | Administración pulmonar de arnm a células objetivo no pulmonares. |
| EP2890398A4 (en) | 2012-08-31 | 2016-03-09 | Five Prime Therapeutics Inc | METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R) |
| US20150366997A1 (en) | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
| EP3431592A1 (en) | 2013-03-14 | 2019-01-23 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| PE20160190A1 (es) | 2013-08-01 | 2016-04-28 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados |
| SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9765147B2 (en) | 2014-10-29 | 2017-09-19 | Five Prime Therapeutics, Inc. | Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer |
| CN107257806B (zh) | 2014-12-22 | 2021-08-10 | 戊瑞治疗有限公司 | 用于治疗pvns的抗csf1r抗体 |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| LT3283527T (lt) | 2015-04-13 | 2021-03-25 | Five Prime Therapeutics, Inc. | Kompleksinė terapija vėžio gydymui |
| US10968277B2 (en) | 2015-10-22 | 2021-04-06 | Jounce Therapeutics, Inc. | Gene signatures for determining ICOS expression |
| EP3448414B1 (en) | 2016-04-25 | 2024-04-17 | Five Prime Therapeutics, Inc. | Nope for treatment of pathological muscle loss and weakness |
| TWI781120B (zh) | 2016-11-02 | 2022-10-21 | 美商永斯醫療股份有限公司 | Ｐｄ-１之抗體及其用途 |
| CN109906030B (zh) | 2016-11-04 | 2022-03-18 | 安健基因公司 | 用于产生仅重链抗体的经基因修饰的非人动物和方法 |
| US20190330376A1 (en) * | 2016-12-29 | 2019-10-31 | Development Center For Biotechnology | Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions |
| WO2018183608A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| EP3634988A4 (en) | 2017-06-06 | 2021-02-24 | Kindred Biosciences, Inc. | ERYTHROPOIETIN AND SIMILAR COMPOUNDS FOR VETERINARY USE |
| JP7391868B2 (ja) | 2017-12-22 | 2023-12-05 | ジョウンセ セラピューティクス， インク． | Ｌｉｌｒｂ２に対する抗体 |
| AU2019302454A1 (en) | 2018-07-09 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to ILT4 |
| WO2020146857A1 (en) * | 2019-01-11 | 2020-07-16 | Arbele Limited | Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof |
| WO2021178001A1 (en) * | 2020-03-05 | 2021-09-10 | Curie Co. Inc. | Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| CN116724051A (zh) | 2020-08-10 | 2023-09-08 | 上海寻百会生物技术有限公司 | 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法 |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712114A (en) * | 1995-06-06 | 1998-01-27 | Basf Aktiengesellschaft | Compositions for expression of proteins in host cells using a preprocollagen signal sequence |
| EP1105508B1 (en) * | 1998-08-17 | 2002-09-04 | Europäisches Laboratorium Für Molekularbiologie (Embl) | Method for purifying biomolecule or protein complexes |
| WO2005082934A2 (en) * | 2004-02-20 | 2005-09-09 | Five Prime Therapeutics, Inc. | Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use |
| US20070264277A1 (en) * | 2004-07-22 | 2007-11-15 | Dirk Behrens | Compositions and Methods of Use for Mgd-Csf in Disease Treatment |
-
2006
- 2006-01-27 WO PCT/US2006/002951 patent/WO2006081430A2/en not_active Ceased
- 2006-01-27 DK DK06719694.9T patent/DK1841874T3/da active
- 2006-01-27 JP JP2007553266A patent/JP2008528033A/ja active Pending
- 2006-01-27 US US11/883,065 patent/US20080286834A1/en not_active Abandoned
- 2006-01-27 EP EP06719694A patent/EP1841874B1/en not_active Not-in-force
- 2006-01-27 AT AT06719694T patent/ATE454455T1/de not_active IP Right Cessation
- 2006-01-27 CA CA002589895A patent/CA2589895A1/en not_active Abandoned
- 2006-01-27 AU AU2006207999A patent/AU2006207999A1/en not_active Abandoned
- 2006-01-27 DE DE602006011574T patent/DE602006011574D1/de active Active
-
2009
- 2009-01-19 JP JP2009009381A patent/JP2009131268A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528033A5 (enExample) | ||
| EP1841874B1 (en) | Leader sequences for directing secretion of polypeptides and methods for production thereof | |
| JP2012531208A5 (enExample) | ||
| JP2553058B2 (ja) | 真核性のバラスト部分を有する融合タンパク質 | |
| CN114395584B (zh) | 表达方法 | |
| RU2017123283A (ru) | Партнеры по слиянию для получения пептидов | |
| JP2005120106A5 (enExample) | ||
| HRP20230991T1 (hr) | Inzulin-fc fuzijski proteini ultradugog djelovanja i metode uporabe | |
| JP2019521643A5 (enExample) | ||
| US20180099994A1 (en) | Nucleic acid construct | |
| TW200732472A (en) | Method for the recombinant expression of a polypeptide | |
| JP2019514361A5 (enExample) | ||
| CN104725515A (zh) | 一种类弹性蛋白多肽与柯萨奇腺病毒受体融合蛋白及其制备方法和应用 | |
| AU2011218243A1 (en) | Fibronectin based scaffold domain proteins that bind IL-23 | |
| CN114981450A (zh) | 人工纳米孔及其相关用途和方法 | |
| RS61391B1 (sr) | Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti | |
| US11053278B2 (en) | Tangential flow filtration based protein refolding methods | |
| WO2003092582B1 (en) | Chimeric ebola virus envelopes and uses therefor | |
| CN101899489A (zh) | 利用内含肽反式剪接模式化生产融合蛋白质 | |
| CN101967493A (zh) | 一种原核表达载体及其应用 | |
| US9803207B2 (en) | Expression vector for production of recombinant proteins in prokaryotic host cells | |
| JP2003504020A5 (enExample) | ||
| JP2019516371A5 (enExample) | ||
| JP2015510770A5 (enExample) | ||
| WO2010001414A1 (en) | Expression of heterologous proteins in bacterial system using a gm-csf fusion tag |